Start here if you're new
what it is
Cencora buys, stores, and delivers prescription drugs for pharmacies, hospitals, and clinics, then sells services around that supply chain.
how it gets paid
Last year Cencora made $321.3B in revenue. U.S. core pharma distribution was the main engine at $231.0B, or 72% of sales.
growth snapshot
Revenue was roughly flat last year at $321.3B. The 3.6% gross margin matters most because this business depends on massive volume.
what just happened
Cencora posted $85.9B in quarterly revenue, while consensus showed an adjusted EPS beat.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
100/100 earnings predictability — you can trust these numbers
22.2x trailing p/e — priced about right
0.7% dividend yield — cash in your pocket every quarter
72.0% return on capital — a money-printing machine
xvary composite: 75/100 — average
What they do
Cencora buys, stores, and delivers prescription drugs for pharmacies, hospitals, and clinics, then sells services around that supply chain.
This business wins on scale. Cencora did $321.3B in trailing revenue with 46,000 employees, and that size matters when your pharmacy, clinic, or oncology office needs drugs on time. Switching costs (hard to change vendors without disruption) are real here, and the proof is a 95/100 price stability score plus a 72.0% return on capital, even with a razor-thin 1.6% operating margin.
How they make money
$321.3B
annual revenue · their business grew +0.0% last year
U.S. core pharma distribution
$231.0B
+0.0%
U.S. specialty distribution
$58.2B
+5.0%
International Healthcare Solutions
$28.9B
+5.0%
Other services & support
$3.2B
+0.0%
The products that matter
wholesale drug logistics
Pharmaceutical Distribution
$321.3B annual revenue
This is the whole machine. It links drug manufacturers with pharmacies and care providers at national scale. The quiet part loud: you are not buying a portfolio of distinct products here. You are buying one massive operating system for moving medicine, and the margin for error is almost as small as the margin for profit.
scale moat
Key numbers
72.0%
return on capital
Return on capital → profit earned for each dollar invested → so what: Cencora turns a low-margin model into a very efficient one.
$321.3B
annual revenue
Scale is the whole point here. You are buying a company that moves an absurd amount of product through a thin-margin pipe.
1.6%
operating margin
Operating margin → revenue left after running the business → so what: there is almost no room for mistakes.
22.2x
trailing p/e
P/E → how many dollars investors pay for $1 of earnings → so what: this is not priced like a sleepy wholesaler.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 2 — safer than 80% of stocks
- price stability 95 / 100
- long-term debt $7.5B (10% of capital)
- net profit margin 1.1% — keeps 1 cents of every dollar in revenue
B++ — functional but not a standout on the balance sheet.
Total return vs. market
You invested $10,000 in COR 3 years ago → it's now worth $22,160.
The index would have given you $14,770.
source: institutional data · total return
What just happened
beat estimates
Cencora posted $85.9B in quarterly revenue, while consensus showed an adjusted EPS beat.
EDGAR showed revenue up 5% vs. prior year and EPS at $2.87, up 15%. Consensus data showed last earnings at $4.08 versus a $4.00 estimate, so reported and adjusted views are telling slightly different stories.
$85.9B
revenue
$2.87
eps
3.6%
gross margin
the number that mattered
The 3.6% gross margin matters most because this business depends on massive volume, and a few basis points can decide whether growth actually reaches shareholders.
-
fourth-quarter results showed continued momentum in the u.s.
-
healthcare solutions segment, where specialty distribution remains the primary growth engine.
-
revenue rose to $83.7 billion and adjusted earnings increased 15%, driven by oncology, retina, and weightmanagement categories.while international consulting remains under pressure, strength in the core u.s. business more than offset those headwinds.
-
the strategic focus on the specialty division continues to sharpen.
-
management raised its long-term earnings growth outlook and laid out a clearer path toward portfolio simplification, grouping non-core assets under ‘other’ and signaling a willingness to exit lower-return businesses over time.investments in retina consultants of america and oneoncology are progressing well, and the company plans to deploy roughly $1 billion through 2030 to expand specialty distribution capacity. these moves should enhance margin durability and reinforce cencora’s leadership in high-growth therapeutic areas.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
Cencora's risk profile is unusually specific. The company moves a huge volume of medicine, but it only keeps 1.1% of revenue as profit. That means you do not need a disaster to hurt earnings. A policy tweak, a reimbursement squeeze, or a few tenths of margin pressure do the job.
med
drug pricing and reimbursement pressure
Government negotiation, reimbursement changes, or pressure elsewhere in the drug supply chain can squeeze distributor economics.
With net margin at 1.1%, the hit does not need to be dramatic. A thinner spread on each prescription would pressure earnings fast.
med
core margin compression
Q4 gross margin was 3.6%. That works when volume is huge, but it leaves very little slack for pricing mistakes, cost inflation, or an unfavorable business mix.
If gross margin slips while revenue keeps rising, you get the unpleasant math of more sales with less operating benefit.
med
specialty expansion execution
Management plans to deploy roughly $1B through 2030 into specialty distribution capacity. That only helps if returns stay high and the rollout stays disciplined.
If that push disappoints, you are left with the same thin-margin distributor, just at a valuation that assumed more mix improvement than the business delivered.
The bear case is not dramatic. That's what makes it real. If pricing gets tighter or margins drift lower, a premium multiple on a low-margin distributor stops making sense.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
gross margin
Q4 gross margin was 3.6%. In this business, a few tenths of a point matter more than flashy revenue headlines.
risk
drug pricing and reimbursement policy
A company with a 1.1% net margin lives close to the edge. Policy changes do not need to be large to move earnings.
calendar
specialty capacity buildout through 2030
Management plans roughly $1B of investment here. You want to see that spend show up in durable growth, not just more fixed cost.
trend
EPS growth versus revenue growth
Recent results showed earnings up 15% on 5% revenue growth. If that spread keeps showing up, the operating model is still getting better.
Analyst rankings
short-term outlook
top 20%
momentum score 2 — in human-speak, analysts think COR should outperform most stocks over the next year.
risk profile
above average
stability score 2 — safer than roughly 80% of stocks, which fits a business this predictable.
chart momentum
average
technical score 3 — the stock is acting normal, not breaking away from the market on its own.
earnings predictability
100 / 100
Management's numbers are unusually reliable. That is rare, and the market usually pays up for it.
source: institutional data
Institutional activity
institutions have been net buying for 3 consecutive quarters — 659 buyers vs. 543 sellers in 3q2025. total institutional holdings: 0.2B shares. net buying for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$315
$588
$356
current price
$452
target midpoint · +27% from current · 3-5yr high: $430 (+20% · 6% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive